AzarGen
About AzarGen
AzarGen is a biotechnology company focused on developing human therapeutic proteins using advanced genetic engineering and synthetic biology techniques in plants. The company's lead therapeutic candidate is a recombinant human surfactant protein (based on rh-SPB) targeted for various respiratory disease conditions. AzarGen has developed proprietary synthetic DNA promoters for various expression platform applications in plant-made pharmaceuticals, synthetic biology, and GMO-crop improvement.YEAR FOUNDED:
2009
LEADERSHIP:
Founder and COO: Cobus Zwiegelaar
CEO: Mauritz Venter
3 articles about AzarGen
-
BioSpace Movers and Shakers for Nov. 19
11/19/2018
Companies bolstered their leadership with additions to boards of directors and c-suite offices. -
Top Oncologist, Dr Samuel Fourie, Joins Advisory Board of AzarGen Biotechnologies
11/14/2018
AzarGen Biotechnologies (Pty) Ltd (Stellenbosch, South Africa), a company focused on developing human therapeutic proteins using advanced genetic engineering and synthetic biology techniques in plants, is pleased to announce that Dr. Samuel Fourie, an oncology specialist, has joined as a Clinical Advisor.
-
AzarGen Granted European Patent For Plant-Made Production Of Recombinant Human Surfactant Protein-B
7/25/2017